Do you want to share your passion for science? FameLab France needs you!
FameLab, the international science communication competition, is launching in France for the first time in 2014 in partnership with AMSCTI, Inserm, CNES, CERN and Paris Diderot – Sorbonne Paris Cité University. Previous candidates have answered questions such as « Will we ever live on Mars? », « Can maths explain the universe? » and «Is 3D printing the second industrial revolution ? ». Candidates, whether researchers or doctoral students, must present their chosen subject in 3 minutes. A panel comprising of science, media, research and public relations professionals will judge each presentation according to the golden 3Cs rule : Content, Clarity and Charisma.
The closing date for all applications is 28 February 2014 (information on http://www.britishcouncil.fr/en/famelab). Regional selections will take place in Lille in association with the Forum Départemental des Sciences, Annecy with the Turbine and the LAPP/LAPTh, Toulouse with Science Animation, and Paris with Paris Diderot – Sorbonne Paris Cité University. The national final will take place in Paris at the end of April at Paris Diderot – Sorbonne Paris Cité University.
FameLab gives candidates the opportunity to:
– meet and connect with other science enthusiasts and become part of the FameLab France and FameLab International network
– share their passion for science with the public
The finalists will win a 2-day masterclass in science communication at CERN in Geneva, working with UK and French science communicators and media trainers to develop their media and presentation skills.
The national finalist chosen in Paris will represent France in the FameLab International final at the Cheltenham Science Festival in the UK in June, competing with candidates from 25 countries.
What the participants say…..
Inserm, with the support of the REACTing network, Public Health France, the country’s university hospitals, and the French College of Teachers in General Practice, is launching COVIREIVAC. This platform for the clinical evaluation of COVID-19 vaccine candidates will make it possible to ...